Last reviewed · How we verify
Preservative-free latanoprost 50µg/ml
Preservative-free latanoprost 50µg/ml is a Prostaglandin F receptor agonist Small molecule drug developed by Medical University of Vienna. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Preservative-free latanoprost 50µg/ml |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Prostaglandin F receptor agonist |
| Target | FP receptor (prostaglandin F receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost binds to prostaglandin F receptors in the eye and enhances drainage of fluid through the uveoscleral (unconventional) pathway, which accounts for approximately 10% of aqueous humor outflow under normal conditions. By increasing this drainage route, the drug effectively lowers intraocular pressure, making it effective for glaucoma and ocular hypertension. The preservative-free formulation reduces ocular surface irritation and toxicity associated with benzalkonium chloride and other preservatives.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation (darkening)
- Conjunctival hyperemia (redness)
- Eyelash growth (hypertrichosis)
- Periocular skin darkening
- Eye irritation or discomfort
Key clinical trials
- Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative-free latanoprost 50µg/ml CI brief — competitive landscape report
- Preservative-free latanoprost 50µg/ml updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI
Frequently asked questions about Preservative-free latanoprost 50µg/ml
What is Preservative-free latanoprost 50µg/ml?
How does Preservative-free latanoprost 50µg/ml work?
What is Preservative-free latanoprost 50µg/ml used for?
Who makes Preservative-free latanoprost 50µg/ml?
What drug class is Preservative-free latanoprost 50µg/ml in?
What development phase is Preservative-free latanoprost 50µg/ml in?
What are the side effects of Preservative-free latanoprost 50µg/ml?
What does Preservative-free latanoprost 50µg/ml target?
Related
- Drug class: All Prostaglandin F receptor agonist drugs
- Target: All drugs targeting FP receptor (prostaglandin F receptor)
- Manufacturer: Medical University of Vienna — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: Preservative-free latanoprost 50µg/ml vs similar drugs
- Pricing: Preservative-free latanoprost 50µg/ml cost, discount & access